Serum magnesium and not vitamin D is associated with better QoL in COPD: A cross-sectional study

Hussein, Sarah Hashim Ali; Nielsen, Lars Peter; Dolberg, Mette Konow Bøgebjerg; Dahl, Ronald

doi:10.1016/j.rmed.2015.03.005

Cited by 12 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 These results are in agreement with other studies confirming low levels of D vitamin in COPD patients. 26 , 27 According to our data, ACOS patients had better lung function parameters and mMRC scores than COPD patients, suggesting that their overall functional status may, perhaps, be better. As compared to the healthy population, ACOS patients also have decreased exercise performance, which may play an important role in the detection of vitamin D deficiency.…”

Section: Discussionmentioning

confidence: 56%

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Odler¹,

Ivancsó²,

Somogyi³

et al. 2015

COPD

View full text Add to dashboard Cite

Introduction The association between vitamin D and clinical parameters in obstructive lung diseases (OLDs), including COPD and bronchial asthma, was previously investigated. As asthma–COPD overlap syndrome (ACOS) is a new clinical entity, the prevalence of vitamin D levels in ACOS is unknown. Aim Our aim was to assess the levels of circulating vitamin D (25-hydroxyvitamin D [25(OH)D]) in different OLDs, including ACOS patients, and its correlation with clinical parameters. Methods A total of 106 men and women (control, n=21; asthma, n=44; COPD, n=21; and ACOS, n=20) were involved in the study. All patients underwent detailed clinical examinations; disease control and severity was assessed by disease-specific questionnaires (COPD assessment test, asthma control test, and modified Medical Research Council); furthermore, 25(OH)D levels were measured in all patients. Results The 25(OH)D level was significantly lower in ACOS and COPD groups compared to asthma group (16.86±1.79 ng/mL and 14.27±1.88 ng/mL vs 25.66±1.91 ng/mL). A positive correlation was found between 25(OH)D level and forced expiratory volume in 1 second ( r =0.4433; P <0.0001), forced vital capacity (FVC) ( r =0.3741; P =0.0004), forced expiratory flow between 25% and 75% of FVC ( r =0.4179; P <0.0001), and peak expiratory flow ( r =0.4846; P <0.0001) in OLD patient groups. Asthma control test total scores and the 25(OH)D level showed a positive correlation in the ACOS ( r =0.4761; P =0.0339) but not in the asthma group. Higher COPD assessment test total scores correlated with decreased 25(OH)D in ACOS ( r =−0.4446; P =0.0495); however, this was not observed in the COPD group. Conclusion Vitamin D deficiency is present in ACOS patients and circulating 25(OH)D level may affect disease control and severity.

show abstract

Section: Discussionmentioning

confidence: 56%

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Odler¹,

Ivancsó²,

Somogyi³

et al. 2015

COPD

View full text Add to dashboard Cite

show abstract

“…Furthermore, both COPD and COVID‐19 reduce mediators that promote vasodilation such as endothelial nitric oxide synthase (eNOS) 28,30,38,136‐141 . It has been demonstrated that COPD severity was associated with serum Mg 2+ deficiency and a worse quality of life in COPD patients 142 . In line with this, Mukerji et al 143 .…”

Section: Magnesium Consumption During Covid‐19 and Post‐covid‐19 Diseasementioning

confidence: 90%

“… 28 , 30 , 38 , 136 , 137 , 138 , 139 , 140 , 141 It has been demonstrated that COPD severity was associated with serum Mg 2+ deficiency and a worse quality of life in COPD patients. 142 In line with this, Mukerji et al. 143 demonstrated that intravenous adjuvant therapy with MgSO 4 improves bronchodilator therapy in acute exacerbations of COPD.…”

Section: Magnesium Consumption During Covid‐19 and Post‐covid‐19 Diseasementioning

confidence: 91%

Antioxidant/anti‐inflammatory effect of Mg²⁺ in coronavirus disease 2019 (COVID‐19)

Arancibia-Hernández

Aranda-Rivera

Cruz-Gregorio

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) causes coronavirus disease 2019 (COVID‐19), characterised by high levels of inflammation and oxidative stress (OS). Oxidative stress induces oxidative damage to lipids, proteins, and DNA, causing tissue damage. Both inflammation and OS contribute to multi‐organ failure in severe cases. Magnesium (Mg 2+ ) regulates many processes, including antioxidant and anti‐inflammatory responses, as well as the proper functioning of other micronutrients such as vitamin D. In addition, Mg 2+ participates as a second signalling messenger in the activation of T cells. Therefore, Mg 2+ deficiency can cause immunodeficiency, exaggerated acute inflammatory response, decreased antioxidant response, and OS. Supplementation with Mg 2+ has an anti‐inflammatory response by reducing the levels of nuclear factor kappa B (NF‐κB), interleukin (IL) ‐6, and tumor necrosis factor alpha. Furthermore, Mg 2+ supplementation improves mitochondrial function and increases the antioxidant glutathione (GSH) content, reducing OS. Therefore, Mg 2+ supplementation is a potential way to reduce inflammation and OS, strengthening the immune system to manage COVID‐19. This narrative review will address Mg 2+ deficiency associated with a worse disease prognosis, Mg 2+ supplementation as a potent antioxidant and anti‐inflammatory therapy during and after COVID‐19 disease, and suggest that randomised controlled trials are indicated.

show abstract

“…Patients with COPD generally have higher smoking status and lower lung function, and these factors were found to be associated with HR-QOL scores. 21) These results suggested that the influence of vitamin D status on HR-QOL score was relatively limited compared to the clinical features of COPD. Our results support the findings of previous cross-sectional studies which did not find associations between vitamin D status and general and COPDspecific HR-QOL scores, including EQ-5D scores and the St. George's Respiratory Questionnaire, in COPD patients.…”

Section: Discussionmentioning

confidence: 92%

Comparison of the Association between Circulating Vitamin D<sub>3</sub> Levels and Clinical Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease: A Prospective Observational Study

Hirai

Shirai

Suzuki

et al. 2019

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Vitamin D has an immune-modulating effect, related to the pathophysiology of asthma and chronic obstructive pulmonary disease (COPD). However, few studies have focused on the difference between patients with asthma and COPD in the association of circulating vitamin D levels with clinical outcomes. We sought to investigate the associations of circulating vitamin D levels with health-related QOL (HR-QOL), severity, and exacerbations. Subjects included 152 asthma patients and 50 COPD patients. We measured plasma concentrations of 25-hydroxyvitamin D 3 [25(OH)D 3 ]. HR-QOL was assessed using the EuroQoL 5-Dimension (EQ-5D) and the 12-item Short Form Health Survey (SF-12) scales. Exacerbations were recorded during a one-year follow-up. Associations between plasma 25 (OH)D 3 concentrations and outcome variables were evaluated using linear regression. Plasma concentrations of 25(OH)D 3 were positively associated with the EQ-5D index value and the SF-12 physical component score in patients with asthma; however, such associations were not observed in patients with COPD. A significant association between severity and plasma concentrations of 25(OH)D 3 was found only in patients with COPD. The hazard ratios (95% confidence interval) of plasma 25(OH)D 3 concentrations (per 1 ng/mL decrease) for time to first exacerbation was 1.38 (1.10-1.75; p 0.006) and 0.95 (0.87-1.03; p 0.179) in patients with COPD and asthma, respectively. Lower concentrations of plasma 25(OH)D 3 contributed to lower HR-QOL in patients with asthma, and were associated with severity and risk of future exacerbations in patients with COPD.

show abstract

Serum magnesium and not vitamin D is associated with better QoL in COPD: A cross-sectional study

Cited by 12 publications

References 39 publications

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Antioxidant/anti‐inflammatory effect of Mg²⁺ in coronavirus disease 2019 (COVID‐19)

Comparison of the Association between Circulating Vitamin D<sub>3</sub> Levels and Clinical Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease: A Prospective Observational Study

Contact Info

Product

Resources

About

Serum magnesium and not vitamin D is associated with better QoL in COPD: A cross-sectional study

Cited by 12 publications

References 39 publications

Vitamin D deficiency is associated with impaired disease control in asthma&ndash;COPD overlap syndrome patients

Vitamin D deficiency is associated with impaired disease control in asthma&ndash;COPD overlap syndrome patients

Antioxidant/anti‐inflammatory effect of Mg2+ in coronavirus disease 2019 (COVID‐19)

Comparison of the Association between Circulating Vitamin D<sub>3</sub> Levels and Clinical Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease: A Prospective Observational Study

Contact Info

Product

Resources

About

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Vitamin D deficiency is associated with impaired disease control in asthma–COPD overlap syndrome patients

Antioxidant/anti‐inflammatory effect of Mg²⁺ in coronavirus disease 2019 (COVID‐19)